Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive topline results from the Phase 3 ARTISTRY-2 trial. The ...

Gilead Sciences said on Monday its experimental HIV treatment was found to be statistically non-inferior to its top-selling ...

Gilead Sciences said on Monday its experimental HIV treatment met the main goal in a late-stage trial. The treatment regimen ...

Gilead said its two-drug bictegravir-lenacapavir tablet was non-inferior to Biktarvy in the Phase 3 ARTISTRY-2 HIV trial.

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

Investigative gel may protect against HIV Vaginal gel with integrase inhibitors shows effectiveness in preventing infection in animal studies. HealthDay News — Use of a vaginal integrase ...

white pills Integrase strand transfer inhibitors (INSTIs) are a generally well-tolerated class of antiretrovirals that have a higher antiviral potency compared with other classes of ART. Integrase ...

Initial regimens composed of an integrase strand transfer inhibitor, specifically bictegravir or dolutegravir, are recommended for most people with HIV. HealthDay News — In a special communication ...

Adults with HIV and obesity who switched from an antiretroviral therapy (ART) regimen with an integrase strand transfer inhibitor (INSTI) and tenofovir alafenamide to doravirine with or without ...

Two posters presented at AMCP Nexus 2022 addressed the cost-effectiveness of guideline-recommended integrase strand transfer inhibitor–based triple therapy in people living with HIV, as well as the ...

SEATTLE--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ: GILD) today announced data from a Phase 2 study evaluating the efficacy, safety and tolerability of a combination of bictegravir (75 mg) (BIC) ...